文献速递重症综合管理与镇静镇痛

危重疾病中的常规衰弱筛查:澳大利亚和新西兰的基于人群的队列研究

Routine Frailty Screening in Critical Illness: A Population-Based Cohort Study in Australia and New Zealand.
PubMed 文献 · Chest · 2021-06-04
一句话结论在澳大利亚和新西兰的ICU中,大规模使用CFS进行衰弱筛查可行且具有预后重要性,衰弱(尤其是CFS≥6)与更差结局相关,包括年轻患者。

该研究为前瞻性队列研究,纳入2018年7月1日至2020年6月30日期间在澳新175个ICU收治的234,568例危重成人患者,入院时用临床衰弱量表(CFS)进行衰弱分类。结果显示19%的患者存在衰弱,衰弱患者院内死亡率16% vs 非衰弱5%(P<.001),谵妄发生率10% vs 4%(P<.001),ICU和住院时间更长,新发慢性护理机构出院比例更高(3% vs 1%)。CFS评分8分的患者院内死亡率39%,而CFS 1分仅2%(OR 7.83, 95%CI 6.39-9.59)。校正疾病严重程度后,衰弱仍显著预测死亡,在50岁以下患者中亦然,将衰弱加入APACHE III-j评分使AUC从0.868提高到0.882(P<.001)。

要点

  • 在175个ICU中,19%(45,245/234,568)的危重成人在入院时被CFS诊断为衰弱。
  • 衰弱患者院内死亡率16% vs 非衰弱5%(P<.001),谵妄10% vs 4%(P<.001)。
  • CFS 8分(非常严重衰弱)患者院内死亡率39%,CFS 1分(非常健康)仅2%,校正后OR 7.83(95%CI 6.39-9.59)。
  • 衰弱与ICU和住院时间延长、新发慢性护理机构出院增加相关(3% vs 1%,P<.001)。
  • 校正疾病严重程度后,衰弱仍显著预测死亡,包括50岁以下患者;加入衰弱使APACHE III-j评分AUC从0.868升至0.882(P<.001)。

适用人群与场景

  • 澳大利亚和新西兰175个ICU收治的危重成人患者,入院时间为2018年7月1日至2020年6月30日。
  • 纳入标准:危重成人患者;排除标准:原文未提及。

诊断标准与关键阈值

  • 使用临床衰弱量表(CFS)在入ICU时进行衰弱分类,CFS评分范围1-9分;原文特别指出CFS评分≥6与更差结局相关。
  • 衰弱定义为入ICU前已存在衰弱(由CFS诊断)。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:前瞻性队列研究(澳大利亚和新西兰双国,175个ICU)。
  • 样本量:234,568例危重成人患者;45,245例(19%)在入ICU前被诊断为衰弱。
  • 主要终点:院内死亡率,衰弱患者16% vs 非衰弱患者5%(P<.001)。
  • 关键次要终点:谵妄(10% vs 4%,P<.001)、ICU和住院时间延长、新发慢性护理机构出院(3% vs 1%,P<.001)。
  • CFS评分8分患者院内死亡率39% vs CFS评分1分患者2%(多变量分类CFS评分8,参考1;OR 7.83,95%CI 6.39-9.59;P<.001)。
  • 校正疾病严重程度后,衰弱仍显著预测死亡,包括50岁以下患者;加入衰弱后APACHE III-j评分的AUC从0.868(95%CI 0.866-0.871)提高到0.882(95%CI 0.879-0.885)(P<.001)。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究;原文未给出证据等级或推荐强度。
  • 局限:原文未明确提及;设计本身为观察性研究,可能存在残余混杂。

对床旁实践的改变

  • 在澳大利亚和新西兰的ICU中,可常规使用CFS进行大规模衰弱筛查,并识别高风险患者(尤其是CFS≥6)。
  • 衰弱筛查可提供预后信息,包括在年轻患者(<50岁)中;但原文未说明基于筛查结果改变治疗决策。

指南或共识出处

  • Chest(原文标题:Routine Frailty Screening in Critical Illness: A Population-Based Cohort Study in Australia and New Zealand.)

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Frailty is associated with poor outcomes in critical illness. However, it is unclear whether frailty screening on admission to the ICU can be conducted routinely at the population level and whether it has prognostic importance.

RESEARCH QUESTION: Can population-scale frailty screening with the Clinical Frailty Scale (CFS) be implemented for critically ill adults in Australia and New Zealand (ANZ) and can it identify patients at risk of negative outcomes?

STUDY DESIGN AND METHODS: We conducted a binational prospective cohort study of critically ill adult patients admitted between July 1, 2018, and June 30, 2020, in 175 ICUs in ANZ. We classified frailty with the CFS on admission to the ICU. The primary outcome was in-hospital mortality; secondary outcomes were length of stay (LOS), discharge destination, complications (delirium, pressure injury), and duration of survival.

RESULTS: We included 234,568 critically ill patients; 45,245 (19%) were diagnosed as living with frailty before ICU admission. Patients with vs without frailty had higher in-hospital mortality (16% vs 5%; P < .001), delirium (10% vs 4%; P < .001), longer LOS in the ICU and hospital, and increased new chronic care discharge (3% vs 1%; P < .001), with worse outcomes associated with increasing CFS category. Of patients with very severe frailty (CFS score, 8), 39% died in hospital vs 2% of very fit patients (CFS score, 1; multivariate categorical CFS score, 8 [reference, 1]; OR, 7.83 [95% CI, 6.39-9.59]; P < .001). After adjustment for illness severity, frailty remained highly significantly predictive of mortality, including among patients younger than 50 years, with improvement in the area under the receiver operating characteristic curve of the Acute Physiology and Chronic Health Evaluation III-j score to 0.882 (95% CI, 0.879-0.885) from 0.868 (95% CI, 0.866-0.871) with the addition of frailty (P < .001).

INTERPRETATION: Large-scale population screening for frailty degree in critical illness was possible and prognostically important, with greater frailty (especially CFS score of ≥ 6) associated with worse outcomes, including among younger patients.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Darvall JN, Bellomo R, Paul E, et al. Routine Frailty Screening in Critical Illness: A Population-Based Cohort Study in Australia and New Zealand. Chest. 2021. PMID: 34089741. doi:10.1016/j.chest.2021.05.049

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。